Lee Chan Henry sold $338K of ONC

Lee Chan Henry (SVP, General Counsel) sold 1,044 shares of BeOne Medicines Ltd. (ONC) at $323.69 ($0.34M total) on 2026-07-30.

Original reporting
SEC EDGAR · Lee Chan Henry
Published Aug 3, 2026, 9:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the specific sale: 1,044 shares sold at $323.6900 on 2026-07-30, totaling $337,932.36, with holdings after the transaction reported as 0 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider fully exited after the sale, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing compensation schedules; without additional context, the signal-to-noise is low.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-08-03, covering a 2026-07-30 sale

Background

The article is a SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by SVP General Counsel Lee Chan Henry of 1,044 shares at $323.69.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new company performance, guidance, or corporate actions. Insider sales are common and the article provides no linkage to material events beyond the transaction details.

Market effects

No sector read-through is provided; this appears company-specific and transaction-specific.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but the filing still lacks any stated reason or linkage to negative fundamentals.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ticker ONC).

  • Lee Chan Henry

    SVP, General Counsel who sold 1,044 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ONCMed

BeOne Medicines Ltd (ONC) Q3 2026 Earnings Call Highlights: Brukinsa Tops $1 Billion

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

$ONCHighAI 8/10

Jefferies raises BeOne Medicines stock price target on solid quarter

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

$ONCHighAI 9/10

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

$ONCMed

BeOne Medicines Receives FDA Priority Review for BRUKINSA Combination in First-Line Mantle Cell Lymphoma

BeOne Medicines (ONC) announced FDA Priority Review for BRUKINSA (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, based on Phase 3 MANGROVE trial results showing 43% reduced risk of disease progression or death. If approved, it would be the first chemotherapy-free regimen for this indication. The company is also seeking approvals in Europe and China. BRUKINSA is already approved for other B-cell malignancies.